Mark H.N. Corrigan

About Mark H. N. Corrigan

Mark H.N. Corrigan, M.D., age 67, has served as an independent director of Wave Life Sciences since September 2019. He holds an M.D. and a B.A. in Psychology from the University of Virginia and completed specialty training in psychiatry at Maine Medical Center and Cornell University, bringing deep clinical and regulatory expertise from senior R&D and CEO roles at multiple biopharma companies .

Past Roles

External Roles

Board Governance

• Committee assignments: Audit Committee member; Research and Development (R&D) Committee Chair; Nominating & Corporate Governance Committee member .
• Independence: Classified as an independent director under Nasdaq rules; board conducts regular executive sessions of independent directors .
• Attendance: In 2024, no director attended fewer than 75% of board and applicable committee meetings; the board met 4 times, committees met 18 times; Audit Committee met 7 times; Nominating & Corporate Governance met 4 times; R&D met 3–4 times .
• Board leadership: Independent Chair is Christian Henry; annual director elections with mandatory retirement and re-election at AGM per Singapore law .

Fixed Compensation

Performance Compensation

Detailed option schedule (Corrigan):

2025 equity policy adjustments (context/signals):

• Initial option 152,400; RSU 25,400; Annual option 76,200; RSU 12,700; refresh grants permitted where initial option expiration within 12 months; rationale: 5-year statutory cap in Singapore prompts larger grants to remain competitive with U.S. peers .

Performance metrics tied to director compensation: None disclosed (director equity is time-based) .

Other Directorships & Interlocks

• Compensation Committee interlocks: None among committee members (Corrigan is not a member); no insider participation .

Expertise & Qualifications

• Extensive clinical development and regulatory leadership from EVP R&D/Group VP roles and CEO experience at public biopharma companies; medical training in psychiatry; recognized for clinical and regulatory expertise as basis for board qualification .
• Financial literacy for audit committee membership; however “audit committee financial expert” designation applies to Henry, Rawcliffe, Tan (not Corrigan) .

Equity Ownership

Note: Beneficial ownership percentages are based on 155,562,665 ordinary shares outstanding (as of Jun 6, 2025) .

Governance Assessment

• Board effectiveness: Corrigan is a highly engaged independent director with multi-committee service (Audit; Nominating & Corporate Governance) and scientific leadership as R&D Committee Chair; attendance met internal benchmarks in 2024, supporting governance quality .
• Alignment: Director compensation is predominantly equity-based (time-based RSUs and options), with specific option/RSU schedules; beneficial ownership is modest (<1%) but option holdings and recurring grants indicate ongoing alignment, constrained by Singapore’s 5-year option term .
• Conflicts/related-party: Proxy details include a related-party transactions section and independence assessment; Corrigan is listed independent, and no Corrigan-specific related-party transactions are identified in the excerpts reviewed. The board monitors director commitments to avoid conflicts .
• Signals: The 2025 proposal to increase director equity sizes (including refresh grants) is a structural response to statutory option term limits rather than a repricing or guaranteed pay escalation; still, investors should watch year-over-year equity mix and dilution implications .
• RED FLAGS: None disclosed specific to Corrigan regarding pledging, hedging, tax gross-ups, options repricing, low attendance, or related-party transactions in the excerpts reviewed .